Innovator Shire announced (in a press release Here) that it has filed a lawsuit in the U.S. District Court of the Southern District of New York against Mylan and Matrix Labs for infringement of Shire’s following Orange Book listed patents for Lanthanum Carbonate (Fosrenol) Chewable tablets 500mg, 750mg and 1gm:
US5968976 (Expiry: Oct 26, 2018): Which coves a pharmaceutical composition for the treatment of hyperphosphataemia comprising lanthanum carbonate
The lawsuit was filed in response to an Abbreviated New Drug Application filed by Mylan seeking USFDA approval to market and sell generic versions of Shire’s 500 mg, 750 mg, and 1 g FOSRENOL® (lanthanum carbonate) products.
Innovator has not asserted two other patents listed in Orange book like US7381428 and US7465465 which will expire on Aug 26, 2024).
Earlier, Ippharmadoc reported Here that innovator confirmed receipt of Paragraph IV notice letter from Barr and Mylan. Innovator has already sued Barr in District Court of the Southern District of New York as reported by us here.
US5968976 (Expiry: Oct 26, 2018): Which coves a pharmaceutical composition for the treatment of hyperphosphataemia comprising lanthanum carbonate
The lawsuit was filed in response to an Abbreviated New Drug Application filed by Mylan seeking USFDA approval to market and sell generic versions of Shire’s 500 mg, 750 mg, and 1 g FOSRENOL® (lanthanum carbonate) products.
Innovator has not asserted two other patents listed in Orange book like US7381428 and US7465465 which will expire on Aug 26, 2024).
Earlier, Ippharmadoc reported Here that innovator confirmed receipt of Paragraph IV notice letter from Barr and Mylan. Innovator has already sued Barr in District Court of the Southern District of New York as reported by us here.
No comments:
Post a Comment